Trasylol Recall Lawsuit

Send to Friend | Bookmark | Live Chat

Recall Alert: Bayer Pharmaceuticals Corp has at the request of the U.S. Food & Drug Administration (FDA) suspended sales of its antibleeding drug Trasylol, amid growing evidence that the drug may be linked to a higher risk of death than that of competing drugs.

Trasylol use has been linked to increased risk of death, kidney or renal failure, heart attacks, strokes and encephalopathy among heart surgery patients.

If you or a loved one have undergone heart surgery and subsequently developed kidney or renal failure and are now undergoing dialysis treatments or have passed away, you should contact us immediately by using the form below or dialing (866) 588-0600. You may be entitled to compensation by filing a Trasylol lawsuit and we can help.

Breaking News: Feb. 17, 2008 -- "One Thousand Lives A Month"

Feb. 17, 2008 --CBS 60 minutes video titled, "One Thousand Lives A Month" Researcher Estimates 22,000 Lives Could Have Been Saved Had Trasylol Been Pulled Earlier

Watch the full length video below.

If you or a loved one have undergone heart surgery and subsequently developed kidney or renal failure and are now undergoing dialysis treatments or have passed away, you should contact us immediately by using the form below or dialing (866) 588-0600. You may be entitled to compensation by filing a Trasylol lawsuit and we can help.

Schmidt & Clark has been actively pursuing Trasylol side effect cases since 2006. The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Trasylol lawsuits. We are handling individual litigation nationwide and currently accepting new Trasylol cases in all 50 states.

FDA Requests Marketing Suspension of Trasylol -- Bayer Suspends Sales of Trasylol

November 5, 2007 --The U.S. Food and Drug Administration (FDA) today announced that, at the agency's request, Bayer Pharmaceuticals Corp. has agreed to a marketing suspension of Trasylol, a drug used to control bleeding during heart surgery, pending detailed review of preliminary results from a Canadian study that suggested an increased risk for death.

According to the Wall Street Journal, Bayer said its decision came in the wake of requests or orders from regulators in the U.S., Canada, Germany and other countries. Trasylol, which is supposed to reduce blood loss and allow patients undergoing heart-bypass surgery to avoid transfusions, is the third drug this year whose sale in the U.S. has been halted under scrutiny from the Food and Drug Administration, a signal of how the agency is weighing safety issues heavily in drug decisions.

Still, the history of Trasylol, which was approved in the U.S. in 1993 and has been tied to high-profile safety concerns at least since early 2006, is likely to draw questions from Congress and plaintiff attorneys.

The drug had world-wide sales of $338 million in 2005. Sales dropped by about a third last year.

What is Trasylol?

Trasylol (Generic: aprotinin) is an injectable prescription drug which inhibits certain enzymes that increase the risk of bleeding during surgery and aids the body's ability to prevent bleeding.

Normally, the drug is given to patients undergoing heart bypass surgery to control blood loss, but has also been used in other surgeries, such as hip replacement surgery.

Trasylol is manufactured by Bayer Pharmaceuticals Corporation and was approved by the Food and Drug Administration in December 1993 to reduce bleeding and the need for blood transfusion in patients undergoing heart surgery.

Do I have a Trasylol Lawsuit?

The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Trasylol lawsuits. We are handling individual litigation nationwide and currently accepting new Trasylol cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field

Trasylol Recall & Lawsuit News (National)

Click here to view the list of recent Press Releases from LegalView - PR.com LegalView recently updated its Heparin information portal on the latest news regarding the contaminated batch of Heparin, which may have sickened hundreds and caused the death of up to 90 individuals. U.S. officials have sourced the contamination to ... LegalView Reports Mine Safety and Health Administration's Reduction of ... - PR.com LegalView alerted mesothelioma blog readers of lowered asbestos exposure allowances, which were amended by the Mine Safety and Health Administration recently. The new limits were reduced by 95 percent of original limits and could increase the number ... LegalView Launches New Practice Area on Blood Thinner Linked to Deadly ... - dBusinessNews.com LegalView unveiled a new practice area detailing the severe side effects of Heparin, a blood thinner commonly used to prevent clots in surgery and other critical care emergencies. However, the blood thinner has been linked to extremely dangerous ... What's Ailing Bayer? - BusinessWeek On Feb. 28, German drug and chemicals conglomerate Bayer ( BAYG.DE ) is expected to report some of its best results in recent years. Analysts forecast sales to rise by more than 10%, to $49 billion, with earnings up 22% before exceptional items and ... 22,000 died amid delayed Bayer drug recall: doctor - Reuters NEW YORK (Reuters) - The lives of 22,000 patients could have been saved if U.S. regulators had been quicker to remove a Bayer AG drug used to stem bleeding during open heart surgery, according to a medical researcher interviewed by CBS Television's ...